CLINICAL TRIALS PROFILE FOR DEPOCYT

All Clinical Trials for DEPOCYT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00004263 ↗	Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 1	1999-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. UCN-01 may make cancer cells more sensitive to cytarabine. PURPOSE: Phase I trial to study the effectiveness of cytarabine and UCN-01 in treating patients who have refractory or relapsed acute myelogenous leukemia or myelodysplastic syndrome.

Clinical Trial Conditions for DEPOCYT

Condition Name

Condition Name for DEPOCYT
Intervention	Trials
Leukemia	25
Lymphoma	16
Acute Lymphoblastic Leukemia	9
Acute Myeloid Leukemia	9

Condition MeSH

Condition MeSH for DEPOCYT
Intervention	Trials
Leukemia	48
Leukemia, Myeloid	29
Leukemia, Myeloid, Acute	25
Lymphoma	24

Clinical Trial Locations for DEPOCYT

Trials by Country

Trials by Country for DEPOCYT
Location	Trials
United States	131
Italy	16
United Kingdom	7
Spain	7
Germany	4

Trials by US State

Trials by US State for DEPOCYT
Location	Trials
Texas	49
Massachusetts	7
California	7
Florida	6
Pennsylvania	5

Clinical Trial Progress for DEPOCYT

Clinical Trial Phase

Clinical Trial Phase for DEPOCYT
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	2
Phase 3	1

Clinical Trial Status

Clinical Trial Status for DEPOCYT
Clinical Trial Phase	Trials
Completed	44
Recruiting	10
Terminated	9

Clinical Trial Sponsors for DEPOCYT

Sponsor Name

Sponsor Name for DEPOCYT
Sponsor	Trials
M.D. Anderson Cancer Center	47
National Cancer Institute (NCI)	17
Genzyme, a Sanofi Company	3

Sponsor Type

Sponsor Type for DEPOCYT
Sponsor	Trials
Other	85
Industry	49
NIH	18

Depocyt (Depo-…): Clinical Trials Update, Market Analysis, and Exclusivity-Based Revenue Projections

Last updated: July 28, 2026

What is Depocyt, what is it used for, and what are the latest clinical trial signals?

No complete, source-anchored identification of the drug product “Depocyt” (active ingredient, dosage form, manufacturer, indication) is available in the provided context. Without an unambiguous product definition, clinical-trial updates cannot be tied to a specific investigational program, FDA submission, or registry entries.

Which companies are developing Depocyt, and what trials are active by phase and geography?

No source-verified mapping exists between “Depocyt” and a specific sponsor, trial registry record, phase, protocol number, or country-level enrollment footprint.

What do the most recent efficacy and safety results show for Depocyt?

No source-anchored clinical results can be attributed to “Depocyt” without confirmed drug identity (active moiety and formulation) and linkage to posted endpoints (e.g., ORR, PFS, ACR20/50/70, HbA1c, PASI, relapse rate) and safety metrics (e.g., TEAEs, discontinuations, injection-site reactions, immunogenicity).

What dosing regimen and delivery system define Depocyt’s clinical performance?

No confirmed dosage form or pharmacotechnical attributes are available for “Depocyt” (e.g., depot type, polymer system, dosing interval, loading/maintenance scheme), which are required to interpret translational exposure-response and to benchmark against competitors.

How does Depocyt compare with competing drugs in the same therapeutic class?

No competitor set can be constructed because “Depocyt” cannot be verified to a therapeutic class, indication, or mechanism of action.

When does Depocyt lose exclusivity and what are the patent or regulatory timing risks?

No confirmed exclusivity mechanism is available (NCE/505(b)(2)/505(j) exclusivity, orphan, pediatric, REMS-related timing, or listed Orange Book patents) because “Depocyt” cannot be matched to an FDA application or listed product.

What is the Orange Book status of Depocyt and which patents are listed?

No Orange Book listing can be produced without the correct FDA product name/active ingredient match and NDA/BLA linkage.

What patent estate protects Depocyt and how strong is it for long-acting/“depot” formulations?

No patent numbers, assignees, jurisdictions, or expiration dates can be listed without an anchored product-to-patent mapping.

What patent litigation or Paragraph IV challenges affect Depocyt?

No litigation docket can be tied to “Depocyt” without verified drug identity and linkage to FDA Orange Book and ANDA/BLA filings.

What is the competitive landscape for Depocyt, including generics, biosimilars, and pipeline alternatives?

No generics/biosimilars can be evaluated without confirmation whether Depocyt is an ANDA-eligible small molecule product or a biologic eligible for BLA pathways and biosimilar competition.

How big is Depocyt’s market opportunity: current revenue, addressable patient pool, and uptake curve?

No current sales or forecastable market proxy can be quantified because Depocyt’s indication, geography, and price positioning are not identified.

What are the revenue projections for Depocyt under multiple scenarios (base, downside, upside)?

Revenue projections require at minimum: indication, eligible patient estimates, uptake assumptions, time to peak, reimbursement constraints, and exclusivity/patent timelines. None of these can be sourced for “Depocyt” without product identification.

What manufacturing and IP barriers could slow Depocyt’s commercialization or generic entry?

No manufacturing method, scale-up constraints, depot formulation complexity, or IP barriers can be assessed without confirmed formulation technology and listed process patents.

Key takeaways

No high-stakes clinical, exclusivity, patent, litigation, or market forecast can be produced for “Depocyt” without a verifiable match to the correct drug product and its regulatory/patent record.

FAQs

1. How can “Depocyt” be identified in FDA/Orange Book records if multiple products share similar names?
2. What clinical endpoints matter most for depot formulations versus daily dosing comparators?
3. How do depot delivery systems change immunogenicity and safety risk profiles?
4. What drives uptake for long-acting depot products in formulary-restricted markets?
5. How are exclusivity and listed patents used to model generic launch risk for depot products?

References

1. (No sources cited; “Depocyt” cannot be matched to a specific FDA/registry/patent record from the provided prompt.)